Prostate cancer (hormone-refractory) - docetaxel (TA101)
Fast, easy summary view of NICE guidance on 'prostate cancer'
Docetaxel is recommended as a possible treatment for men with hormone-refractory metastatic prostate cancer.
- It should be given only if the man is well enough to care for himself with occasional assistance.
- Treatment should be stopped at the end of a planned course of up to 10 cycles (or 'rounds') of docetaxel.
- The treatment should be stopped early if the man experiences serious side effects, or if the disease is getting worse.
NICE does not recommend using docetaxel again if the disease comes back after the first course of treatment has finished.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: prostate cancer
This page was last updated: 26 June 2012
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA101 Docetaxel ar gyfer trin canser metastatig y brostad nad yw'n ymateb mwyach i driniaeth i atal hormonau: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
- Multiple guidance audit tool
- TA101 Prostate cancer (hormone-refractory) - docetaxel: analysis of cost impact
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.